PRESS RELEASE

The Cellfina® System Recognized by RealSelf as Most Worth It Award Winner

Raleigh, N.C., USA – June 5, 2017 – Merz Aesthetics, a division of Merz Pharma Group, announced today that the Cellfina® System has been named a 2016 RealSelf Most Worth It award winner in the “Cellulite Treatment” category.

More than 9 million people visit RealSelf each month to find out which providers and aesthetic treatments live up to their promise of delivering results, including whether the treatment was “worth it.” The Cellfina® System is among 12 nonsurgical treatments recognized by RealSelf as leaders in their categories, achieving the highest consumer satisfaction rates1 in 2016.

“To be awarded as the Most Worth It cellulite treatment in the first RealSelf Most Worth It awards is a true testament of the Cellfina® System’s proof of performance,” said Patrick Urban, Chief Commercial Officer of Merz North America. “This innovative technology continues to be recognized for delivering proven results and garnering a high rate of patient satisfaction.”

The Cellfina® System is the only U.S. FDA-cleared and E.U. CE-Marked, minimally invasive procedure that effectively improves the appearance of cellulite with results that last at least three years. The Cellfina® System combines highly advanced, proprietary technology with a well-established procedure called subcision, to treat the structural cause of cellulite. The Cellfina® System is currently available in the U.S., Canada, and select markets in Europe.

For more information on Cellfina®, visit https://global.cellfina.com/

To find out more about the Cellfina® System and its 2016 RealSelf Most Worth It award win, visit www.realself.com/guide/most-worth-it-2016.

The Cellfina® System is CE Mark-certified for long-term reduction of cellulite, up to three years, by precise release of targeted structural tissue (fibrous septae). The Cellfina® System is FDA-cleared for long-term improvement in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating no significant reduction in treatment benefits up to three years of observation. Safety and effectiveness in other anatomical areas have not been established. The most common side effects reported were soreness, tenderness, and bruising. The Cellfina® System is only available through a licensed physician. For full product and safety information, refer to the Instructions for Use.
About Merz Pharma Group
With approximately 3,000 employees and 34 subsidiaries, Merz is a leading global provider in the fields of Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. In addition to its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy to treat neurologically induced movement disorders. OTC medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, the Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

Media Contact:
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Tel.: +49 151 4249 1466
E-Mail: mariana.smith@merz.com

Merz North America
Corporate Communications
Emily Browder
Tel.: +1 919 582 8114
E-Mail: Emily.Browder@merz.com